Journal for ImmunoTherapy of Cancer – Page 54

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

15 de October de 2025 by

Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and timely can be ch…

Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression

13 de October de 2025 by Li, W., Chen, J., Li, J., Wang, S., Chen, Z., Zhao, L., Zhao, Y., Gu, L., Liu, J., Zhang, Y., Yang, X., Chen, T., Guo, Z.

Background
Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable success in hematologic malignancies; however, its efficacy in solid tumors remains limited. A major barrier is the immunosuppressive tumor microenvironment (TME), wh…

Inhibition of osteosarcoma lung metastases by {beta}-glucan and CD40 agonist is mediated by activation of macrophages and NK cells

13 de October de 2025 by Shrestha, P., Shrestha, R., Kleinerman, E. S.

Background
Osteosarcoma (OS) lung metastases remain a significant therapeutic challenge. Innate immune activation is a promising therapeutic approach. Innate immune agonists can modulate the tumor immune microenvironment and improve therapeutic respon…

Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors

10 de October de 2025 by

Background
Solid tumors comprise approximately 60% of all pediatric cancers. Relapsed or refractory tumors of the central nervous system (CNS), such as atypical teratoid/rhabdoid tumors (AT/RTs), are the leading cause of death in children with cancer….

ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer

10 de October de 2025 by Wen, S., Du, X., Zhu, M., Huang, C., Lin, Z., Li, M., Hu, B., Wang, X., Jiang, F., Zhou, G., Zhu, W., Yu, G., Xu, C., Shen, B.

Background
Metastatic recurrence poses a significant challenge in cancer treatment, impacting patient survival and prognosis. Understanding the biological mechanisms behind it is essential for improving treatment strategies and patient outcomes. Lung …

Correction: Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma

9 de October de 2025 by Journal for ImmunoTherapy of Cancer current issue

Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case

9 de October de 2025 by

Cholangiocarcinomas are rare but aggressive liver tumors of high lethality with scarce treatment options. Here we report on the follow-up of a patient diagnosed with an intrahepatic cholangiocarcinoma who experienced repeated tumor recurrences includi…

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy

9 de October de 2025 by

Background
Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). However, a comprehensive analysis of germline deter…

Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors

9 de October de 2025 by Yang, S., Wang, W., Rao, Q., Xu, Y., Zhang, S., Qu, Y., Zhuang, Q., Mao, J., Sun, L., Geng, D., Xu, D., Zhao, C.

Background
Chimeric antigen receptor (CAR)-T cell therapy represents an innovative and potentially revolutionary modality in cancer treatment. Despite their great success in treating blood cancers, CAR-T therapies exhibit significantly lower effective…

Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response

9 de October de 2025 by Edwards, J. M., Senthi, S., Smith, R., Burridge, H., Owens, C., Shackleton, M., Andrews, M. C., van Zelm, M. C.

Background
Despite the success of combined cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) immune checkpoint blockade (cICB), the majority of patients with melanoma fail to respond or experience severe t…